Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of efficacy of tocilizumab and TNF inhibitor as monotherapy and combination with conventional synthetic disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA) after the use of at least one biologic DMARD

Next Previous
Search
Trial Profile

Comparison of efficacy of tocilizumab and TNF inhibitor as monotherapy and combination with conventional synthetic disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA) after the use of at least one biologic DMARD

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 15 May 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tocilizumab (Primary) ; Disease-modifying antirheumatics; Tumour necrosis factor inhibitors
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 15 May 2018 New trial record
    • 05 May 2018 Results published in the Annals of the Rheumatic Diseases

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top